Furthermore, although there is no literature on the association of myristoyl with T1D, myristoylated Akt has been reported to be associated with improved prognosis in T1D mice.[47] Additionally, 1-myristoyl-2-arachidonoyl-GPC was reported to have a role in preserving residual β-cell function.[48] These findings suggest that SM, dihydrosphingomyelin, and myristoyl are associated with a reduced risk of T1D, pointing to myristoyl dihydrosphingomyelin (d18:0/14:0) as a potential protective factor for T1D. Here, AKT1 is linked to type 1 diabetes mellitus.